H
Haider Abbas
Researcher at University of the Sciences
Publications - 222
Citations - 5628
Haider Abbas is an academic researcher from University of the Sciences. The author has contributed to research in topics: Cloud computing & Resistive random-access memory. The author has an hindex of 29, co-authored 198 publications receiving 3528 citations. Previous affiliations of Haider Abbas include National University of Science and Technology & New Cross Hospital.
Papers
More filters
Journal ArticleDOI
Fuzziness based semi-supervised learning approach for intrusion detection system
TL;DR: A novel fuzziness based semi-supervised learning approach by utilizing unlabeled samples assisted with supervised learning algorithm to improve the classifier's performance for the IDSs is proposed.
Journal ArticleDOI
A Manufacturing Big Data Solution for Active Preventive Maintenance
Jiafu Wan,Shenglong Tang,Di Li,Shiyong Wang,Chengliang Liu,Haider Abbas,Athanasios V. Vasilakos +6 more
TL;DR: The manufacturing big data method used for active preventive maintenance has the potential to accelerate implementation of Industry 4.0.
Journal ArticleDOI
Blockchain's adoption in IoT: The challenges, and a way forward
TL;DR: A systematic study of the peculiarities of the IoT environment including its security and performance requirements and progression in blockchain technologies is carried out and a way forward is proposed to resolve some of the significant challenges to the blockchain's adoption in IoT.
Journal ArticleDOI
Cloud-Assisted IoT-Based SCADA Systems Security: A Review of the State of the Art and Future Challenges
TL;DR: The focus of the study presented in this paper is to highlight the security challenges that the industrial SCADA systems face in an IoT-cloud environment and provides the existing best practices and recommendations for improving and maintaining security.
Journal ArticleDOI
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
Susan J Dutton,D. R. Ferry,Jane M Blazeby,Jane M Blazeby,Haider Abbas,Asa Dahle-Smith,Wasat Mansoor,Joyce Thompson,Mark Harrison,Anirban Chatterjee,Stephen Falk,Angel Garcia-Alonso,D. Fyfe,Richard A Hubner,Tina Gamble,Lynnda Peachey,Mina Davoudianfar,Sarah Pearson,Patrick Julier,Janusz Jankowski,Rachel Kerr,Russell D. Petty +21 more
TL;DR: The use of gefitinib as a second-line treatment in oesophageal cancer in unselected patients does not improve overall survival, but has palliative benefits in a subgroup of patients with short life expectancy.